WASHINGTON — The Trump administration is looking at “comprehensive” changes to the so-called 340B program as part of its work to lower prescription drug prices, Health and Human Services Secretary Alex Azar said Monday, in a surprisingly direct speech before a ballroom full of representatives for the hospitals and clinics that have called for stronger protections for the program.

The federal drug discount program known as 340B has been the subject of an increasingly contentious debate that pits pharmaceutical companies, which want to rein in the federal drug discount program, against the participating hospitals that receive the discounts. And Azar made it clear Monday that he’s far more interested in the reforms the pharmaceutical industry has proposed — to limit and restrain the program — than the changes hospitals have pushed that would protect their participation.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy